• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why CorMedix Are Trading Lower By 22%; Here Are 20 Stocks Moving Premarket

    6/29/23 8:18:31 AM ET
    $AHG
    $BB
    $BDTX
    $BTTR
    Real Estate
    Real Estate
    Computer Software: Prepackaged Software
    Technology
    Get the next $AHG alert in real time by email

    Gainers

    • Eco Wave Power Global AB (NASDAQ:WAVE) shares surged 123% to $3.48 in pre-market trading after dropping over 8% on Wednesday.
    • Kintara Therapeutics, Inc. (NASDAQ:KTRA) shares gained 33.1% to $3.98 in pre-market trading after the company secured $2.0 million National Institutes of Health SBIR grant to support clinical development of REM-001.
    • Fangdd Network Group Ltd. (NASDAQ:DUO) shares rose 21.7% to $0.9367 in pre-market trading after dropping 11% on Wednesday. FangDD Network Group recently received Nasdaq notice regarding minimum bid price requirements.
    • BlackBerry Limited (NYSE:BB) shares rose 18.5% to $5.94 in pre-market trading after the company reported better-than-expected fiscal first-quarter results.
    • Emerson Radio Corp. (NYSE:MSN) shares gained 18.5% to $0.64 in pre-market trading.
    • Akso Health Group (NASDAQ:AHG) shares climbed 18.2% to $0.39 in pre-market trading after gaining around 5% on Wednesday.
    • Better Choice Company Inc. (NYSE:BTTR) rose 16.7% to $0.2690 in pre-market trading after declining around 8% on Wednesday. Better Choice recently announced a $5 million investment from Alphia, establishing a direct manucafturing relationship.
    • AIM ImmunoTech Inc. (NYSE:AIM) gained 15.8% to $0.6830 in pre-market trading after gaining around 5% on Wednesday. AIM ImmunoTech recently announced publication of findings from a pre-clinical study evaluating Ampligen in the treatment of pancreatic cancer in the American Journal of Cancer Research.
    • ZIVO Bioscience, Inc. (NASDAQ:ZIVO) rose 14.5% to $2.69 in pre-market trading after declining over 3% on Wednesday.
    • Shapeways Holdings, Inc. (NYSE:SHPW) gained 11.9% to $3.30 in pre-market trading after the company announced securing two new Tier 1 supplier contracts.

    Losers

    • CorMedix Inc. (NASDAQ:CRMD) fell 21.6% to $3.97 in pre-market trading after the company reported pricing of $40 million public offering of common stock and pre-funded warrants.
    • iMedia Brands, Inc. (NASDAQ:IMBI) fell 14.1% to $0.1656 in pre-market trading after jumping 20% on Wednesday.
    • Novan, Inc. (NASDAQ:NOVN) fell 13.4% to $0.3971 in pre-market after gaining over 12% on Wednesday.
    • Knightscope, Inc. (NASDAQ:KSCP) fell 11.4% to $0.6201 in pre-market trading after jumping 52% on Wednesday. The company's CEO made comments about 2023 projections on the Stock Day podcast.
    • Minerva Neurosciences, Inc. (NASDAQ:NERV) fell 10.1% to $9.16 in pre-market trading. Minerva Neurosciences shares jumped over 69% on Wednesday after the company announced a $20 million private placement priced at a premium to the market.
    • Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) shares dropped 10% to $5.16 in pre-market trading after the company reported a $75 million proposed public offering of common stock.
    • Surgalign Holdings, Inc. (NASDAQ:SRGA) shares dropped 10% to $0.27 in pre-market trading after gaining 11% on Wednesday. Surgalign Holdings’ subsidiary Holo Surgical was granted European Patent Number EP3751516 titled "Autonomous Multidimensional Segmentation Of Anatomical Structures On Three-Dimensional Medical Imaging."
    • Centogene N.V. (NASDAQ:CNTG) fell 8.9% to $1.44 in pre-market trading after jumping 34% on Wednesday. CENTOGENE and Lifera recently formed a Saudi Arabian joint venture.
    • Appreciate Holdings, Inc. (NASDAQ:SFR) fell 8.1% to $0.3739 in pre-market trading after gaining 7% on Wednesday.
    • Jaguar Health, Inc. (NASDAQ:JAGX) shares fell 7% to $0.4820 in pre-market trading. Napo Pharmaceuticals, a Jaguar Health Company, submitted investigational new drug application to the FDA for microvillus inclusion disease.

     

    Now Read This: Investor Optimism Improves After Nasdaq Settles Higher

    Get the next $AHG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AHG
    $BB
    $BDTX
    $BTTR

    CompanyDatePrice TargetRatingAnalyst
    Minerva Neurosciences Inc
    $NERV
    4/15/2026$14.00Mkt Outperform
    Citizens
    Black Diamond Therapeutics Inc.
    $BDTX
    12/3/2025Buy → Neutral
    Guggenheim
    Black Diamond Therapeutics Inc.
    $BDTX
    11/18/2025$9.00Overweight
    Piper Sandler
    CorMedix Inc.
    $CRMD
    10/20/2025$14.00Hold → Buy
    D. Boral Capital
    Black Diamond Therapeutics Inc.
    $BDTX
    10/16/2025$8.00Buy
    Stifel
    BlackBerry Limited
    $BB
    10/3/2025$5.00Buy → Hold
    TD Securities
    Black Diamond Therapeutics Inc.
    $BDTX
    9/4/2025$8.00Buy
    Guggenheim
    Black Diamond Therapeutics Inc.
    $BDTX
    7/1/2025$11.00Outperform
    Raymond James
    More analyst ratings

    $AHG
    $BB
    $BDTX
    $BTTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citizens initiated coverage on Minerva Neurosciences with a new price target

    Citizens initiated coverage of Minerva Neurosciences with a rating of Mkt Outperform and set a new price target of $14.00

    4/15/26 8:09:21 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Black Diamond Therapeutics downgraded by Guggenheim

    Guggenheim downgraded Black Diamond Therapeutics from Buy to Neutral

    12/3/25 12:43:23 PM ET
    $BDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Piper Sandler resumed coverage on Black Diamond Therapeutics with a new price target

    Piper Sandler resumed coverage of Black Diamond Therapeutics with a rating of Overweight and set a new price target of $9.00

    11/18/25 8:20:21 AM ET
    $BDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AHG
    $BB
    $BDTX
    $BTTR
    SEC Filings

    View All

    SEC Form DEFA14A filed by Minerva Neurosciences Inc

    DEFA14A - Minerva Neurosciences, Inc. (0001598646) (Filer)

    4/23/26 7:02:08 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Minerva Neurosciences Inc

    DEF 14A - Minerva Neurosciences, Inc. (0001598646) (Filer)

    4/23/26 7:00:34 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SD filed by BlackBerry Limited

    SD - BLACKBERRY Ltd (0001070235) (Filer)

    4/22/26 12:45:38 PM ET
    $BB
    Computer Software: Prepackaged Software
    Technology

    $AHG
    $BB
    $BDTX
    $BTTR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 17, 2023 - FDA Roundup: November 17, 2023

    For Immediate Release: November 17, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, to mark the 15th anniversary of the FDA foreign offices, the FDA published an interview with Susan Winckler, who was FDA chief of staff when the first office was opened in Beijing on November 19, 2008. Winckler is now CEO of the Reagan-Udall Foundation

    11/17/23 4:18:44 PM ET
    $BMY
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DEFENCATH issued to CORMEDIX INC

    Submission status for CORMEDIX INC's drug DEFENCATH (ORIG-1) with active ingredient TAUROLIDINE AND HEPARIN SODIUM has changed to 'Approval' on 11/15/2023. Application Category: NDA, Application Number: 214520, Application Classification: Type 1 - New Molecular Entity and Type 4 - New Combination

    11/15/23 9:53:06 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $BB
    $BDTX
    $BTTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Yaldoo Laith L bought $14,998 worth of shares (1,543 units at $9.72) (SEC Form 4)

    4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

    3/3/26 4:06:40 PM ET
    $ZIVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Strome Mark E bought $195,400 worth of shares (20,000 units at $9.77) (SEC Form 4)

    4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

    2/17/26 6:22:38 AM ET
    $ZIVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Yaldoo Laith L bought $24,997 worth of shares (2,434 units at $10.27) (SEC Form 4)

    4 - Zivo Bioscience, Inc. (0001101026) (Issuer)

    2/12/26 9:21:50 AM ET
    $ZIVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $BB
    $BDTX
    $BTTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by O'Connor James Joseph

    4 - Minerva Neurosciences, Inc. (0001598646) (Issuer)

    4/22/26 4:55:18 PM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider O'Connor James Joseph

    3 - Minerva Neurosciences, Inc. (0001598646) (Issuer)

    4/22/26 4:53:56 PM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Rose Eric James

    3 - Knightscope, Inc. (0001600983) (Issuer)

    4/16/26 5:29:30 PM ET
    $KSCP
    Telecommunications Equipment
    Telecommunications

    $AHG
    $BB
    $BDTX
    $BTTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Eco Wave Power to Present at Israel Tech Week Miami 2026

    Founder and CEO Inna Braverman to highlight wave energy innovation, global project momentum, and the Company's role in powering next-generation AI and coastal infrastructureMiami, Florida--(Newsfile Corp. - April 23, 2026) - Eco Wave Power Global AB (publ) (NASDAQ:WAVE) ("Eco Wave Power" or the "Company"), a leading onshore wave energy technology company, today announced that it will participate in Israel Tech Week Miami 2026, one of the leading events connecting innovators, investors, entrepreneurs, and technology leaders from Israel, the United States, and global markets.As part of the program, Eco Wave Power's Founder and Chief Executive Officer, Inna Braverman, will present on April 29,

    4/23/26 8:30:00 AM ET
    $WAVE
    Electric Utilities: Central
    Utilities

    Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting

    Poster also to be presented on the Phase 2 data of silevertinib in recurrent EGFRm NSCLC patients Trial-in-progress poster to be presented on the randomized Phase 2 trial of silevertinib in patients with newly diagnosed EGFRvIII-positive GBM CAMBRIDGE, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced multiple presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 – June 2, 2026, in Chicago. Details for the Oral Presentation: Session Type/Title: Rapid Oral

    4/21/26 10:40:00 AM ET
    $BDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BlackBerry and The IP Company Partner to Bring Certified Secure Communications to Naval and Military Environments

    AMSTERDAM, April 16, 2026 /PRNewswire/ -- The IP Company today announced a strategic partnership with BlackBerry Secure Communications, a division of BlackBerry Limited (NYSE:BB) (TSX:BB) to bring highly secure, certified communications capabilities to naval and military environments worldwide. Through this partnership, the companies will explore the integration of BlackBerry® SecuSUITE®, certified to the highest international security standards, into The IP Company's proven Wireless Communication & Messaging System (WCMS), a proven platform deployed across naval fleets for more

    4/16/26 9:59:00 AM ET
    $BB
    Computer Software: Prepackaged Software
    Technology

    $AHG
    $BB
    $BDTX
    $BTTR
    Leadership Updates

    Live Leadership Updates

    View All

    Minerva Announces Leadership Transition

    BURLINGTON, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced a leadership transition with the appointment of Jim O'Connor as Chief Business Officer (CBO), effective April 21, 2026, as Geoff Race, the Company's President, has elected to leave the company. Mr. Race will continue to be involved with Minerva as a consultant. Mr. Race joined Minerva in 2010 and went on to serve in multiple executive roles including Executive Vice President and Chief Financial Officer, Chief Business Officer, and most recently President

    4/2/26 4:05:00 PM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CorMedix Therapeutics Announces Leadership and Board Updates

    BERKELEY HEIGHTS, N.J., Jan. 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced an addition to its executive leadership team and updates to its Board of Directors. CorMedix CEO Joseph Todisco has signed an extended employment contract, reaffirming his long-term commitment to the organization. In addition to his role as CEO, Mr. Todisco will also assume the role of Chairman of the Board of Directors, succeeding Myron Kaplan. Mr. Kaplan will transition into a newly created board position of Lead Independent Director. "Under t

    1/8/26 8:05:00 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors

    BURLINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the appointment of Dr. Inderjit Kaul, Chief Medical Officer of Draig Therapeutics, to the board of directors. Dr. Kaul will also serve as a consultant to the Company for the future clinical development of roluperidone. Last month, the Company announced successfully raising up to $200 million in a private placement to fund a confirmatory Phase 3 trial for roluperidone for the treatment of negative symptoms in patients with schizophrenia, resubmission of it

    11/19/25 8:30:00 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $BB
    $BDTX
    $BTTR
    Financials

    Live finance-specific insights

    View All

    Eco Wave Power Reports Strong Operational Progress and Files 2025 Annual Report on Form 20-F

    Company completes first U.S. wave energy pilot project, submits final report to Shell, records highest energy generation at Israeli project, advances megawatt-scale project in Portugal and supports Taiwan project development, while reducing Q4 operating expenses by 24%Stockholm, Sweden--(Newsfile Corp. - March 12, 2026) - Eco Wave Power Global AB (publ) (NASDAQ:WAVE) ("Eco Wave Power" or the "Company"), a leading onshore wave energy technology company, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 (the "Annual Report") with the U.S. Securities and Exchange Commission (the "SEC").The Annual Report, which includes the Company's aud

    3/12/26 8:30:00 AM ET
    $WAVE
    Electric Utilities: Central
    Utilities

    CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    ‒ Q4 2025 Net Revenue of $128.6 million ‒ ‒ Pro Forma Full Year 2025 Net Revenue of $401.3 million ‒   ‒ Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ PARSIPPANY, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the fourth quarter and full-year ended December 31, 2025 and provided an update on its business. Recent Corporate Highlights: CorMedix announces $128.6 million of net revenue for the fourth qu

    3/5/26 7:30:00 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026

    BERKELEY HEIGHTS, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Thursday, March 5, 2026, and will host a corporate update conference call at 8:30am Eastern Time. Thursday, March 5th @ 8:30am ETDomestic:   1-844-676-2922International: 1-412-634-6840Webcast:   Webcast Link   About CorMedix CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializi

    3/2/26 8:30:00 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AHG
    $BB
    $BDTX
    $BTTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by AIM ImmunoTech Inc.

    SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)

    12/17/24 4:11:23 PM ET
    $AIM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Fangdd Network Group Ltd.

    SC 13G - Fangdd Network Group Ltd. (0001750593) (Subject)

    12/16/24 4:26:40 PM ET
    $DUO
    Real Estate
    Finance

    Amendment: SEC Form SC 13G/A filed by Fangdd Network Group Ltd.

    SC 13G/A - Fangdd Network Group Ltd. (0001750593) (Subject)

    12/16/24 4:24:27 PM ET
    $DUO
    Real Estate
    Finance